Pasar al contenido principal

TERAPEUTICOS VIVOS BACTERIANOS CONTRA LOS CARCINOMAS DE VEJIGA Y COLON BASADOS EN CEPAS SINTETICAS INYECTORAS DE E. COLI (SIEC) DIRIGIDAS A CELULAS Y QUE LIBERAN TOXINAS ART

PID2023-148228OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Progress in engineered bacterial cancer therapies

  • Pico-Sánchez, Eva
  • Fernández, Luis Ángel
Engineered bacteria are emerging as powerful tools in the development of cancer therapies, driven by advances in synthetic biology and tumor immunology. These microbes preferentially colonize solid tumors, where they can deliver therapeutic agents directly to malignant cells and into the tumor microenvironment, inducing tumor cell death and activating robust anti-tumor immune responses. Current strategies include programming bacteria to secrete toxins, tumor-suppressor or pro-apoptotic proteins, and to mediate targeted intracellular delivery. Bacteria can also be engineered to sense tumor-specific metabolites and to adhere to tumor-associated cell surface antigens, further enhancing selectivity and safety. Engineered strains synergize with immunotherapies — including immune checkpoint inhibitors and chimeric antigen receptor-T cells — and can stimulate both innate and adaptive immune responses, even at distant metastatic sites. Here, we review recent progress in this field, with a focus on engineering strategies and their effectiveness in preclinical in vivo tumor models, and outline prospects for future developments and remaining challenges., This work was supported by grant PID2023-148228OB-I00 by MICIU/AEI/10.13039/501100011033 and FEDER, EU; and by Horizon-EIC-PathfinderOpen 101130574 from European Union., Peer reviewed, Sin experimentacion animal ni uso de NAMs